PLX
Protalix BioTherapeutics, Inc.
NYSE MKT
People also watch:PSTIPIPXNPTTHLDCGEN
0.64-0.01 (-1.26%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close0.65
Open0.64
Bid0.64 x 3500
Ask2.50 x 800
52wk Range0.61 - 1.78
Day's Range0.63 - 0.67
Volume249,286
Avg Vol (3m)76,712
As of 4:00 PM EDT. Market closed.
  • Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016
    Capital Cube2 months ago

    Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016

    Click here to see latest analysisProtalix Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2016.HighlightsSummary numbers: Revenues of USD 0.68 million, Net Earnings of USD -8.53 million.Gross margins widened from -13.95% to 22.97% compared to the same period last year, operating (EBITDA) margins now -1,274.96% from -601.45%.Change in operating cash flow of […] (Read more...) The post Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 19, 2016 appeared first on CapitalCube.

  • Associated Press2 months ago

    Protalix reports 1Q loss

    On a per-share basis, the Carmiel, Israel-based company said it had a loss of 9 cents. The drug developer posted revenue of $679,000 in the period. The company's shares closed at 80 cents. A year ago, ...